Join the 'Panuveitis' group to help and get support from people like you.
Posted 8 Sep 2016 by Drugs.com
WEDNESDAY, Sept. 7, 2016 – People with chronic eye inflammation known as uveitis may be able to keep the condition at bay with the immune-suppressing drug Humira (adalimumab), a new study finds. "Humira doesn't cure uveitis, but it does cause it to become quiet," said lead researcher Dr. Glenn Jaffe. He's a professor of ophthalmology at Duke University School of Medicine in Durham, N.C., and a consultant for Humira's maker, AbbVie. "The hope is while the disease is in a quiet state, the disease activity just burns itself out – but it can also come back," he said. The U.S. Food and Drug Administration approved Humira for the treatment of uveitis in June. The results of the study were published Sept. 8 in the New England Journal of Medicine. The study was funded by AbbVie. Uveitis – a term used to describe a group of inflammatory diseases inside the eye – can cause loss of vision and ... Read more
Related support groups: Prednisone, Eye Conditions, Humira, Methylprednisolone, Prednisolone, Hydrocortisone, Medrol, Cortisone, Dexamethasone, Triamcinolone, Betamethasone, Budesonide, Decadron, Entocort, Uveitis, Solu-Medrol, Entocort EC, Medrol Dosepak, Cortef, Celestone
AbbVie's Humira (adalimumab) Receives FDA Approval to Treat Adults with Non-Infectious Intermediate, Posterior and Panuveitis
Posted 2 Jul 2016 by Drugs.com
NORTH CHICAGO, Ill., June 30, 2016 /PRNewswire/ – AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Humira (adalimumab) for the treatment of non-infectious intermediate, posterior and panuveitis. Humira is now the first and only FDA-approved non-corticosteroid therapy available for adults with non-infectious intermediate, posterior and panuveitis. This approval marks the 10th approved indication for Humira in the United States for immune-mediated diseases. This month, the European Commission also approved Humira in the European Union for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. "We are pleased to ... Read more